{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:14:04Z","timestamp":1783372444291,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.arteri.2026.500956","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:18:54Z","timestamp":1783369134000},"page":"500956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Papel de los inhibidores del factor xi como nueva estrategia anticoagulante en la prevenci\u00f3n y tratamiento de la trombosis arterial"],"prefix":"10.1016","author":[{"given":"Jos\u00e9 A.","family":"P\u00e1ramo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2026.500956_bib0135","article-title":"SEA 2026 Standards for Global Control of Cardiovascular Risk","volume":"38","author":"Mostaza","year":"2026","journal-title":"Clin Invest Arterioscler"},{"key":"10.1016\/j.arteri.2026.500956_bib0140","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2026.500956_bib0145","article-title":"Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world evidence (SIESTA-A study)","volume":"16","author":"Montero-Belosa","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arteri.2026.500956_bib0150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2026.500956_bib0155","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"JACC"},{"key":"10.1016\/j.arteri.2026.500956_bib0160","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: Moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arteri.2026.500956_bib0165","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtha.2024.12.003","article-title":"New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis","volume":"23","author":"Barnes","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arteri.2026.500956_bib0170","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.3390\/jcm11216314","article-title":"Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders","volume":"11","author":"Campello","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0175","first-page":"437","article-title":"Factor XI\/XIa inhibition: The arsenal in development for a new therapeutic target in cardio-and cerebrovascular disease","volume":"9","author":"Badimon","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.arteri.2026.500956_bib0180","first-page":"73","article-title":"Factor XI inhibitors: A new era in antithrombotic therapy","volume":"162","author":"Paramo","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.arteri.2026.500956_bib0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1358863X231206778","article-title":"Factor XI\/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review","volume":"29","author":"Prakash","year":"2024","journal-title":"Vasc Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0190","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nature Rev Cardiol"},{"key":"10.1016\/j.arteri.2026.500956_bib0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis; FXI-ASO TKA Investigators","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruft","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0205","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jtha.2025.11.033","article-title":"Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants","volume":"24","author":"Dobbing","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.arteri.2026.500956_bib0210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study; PACIFIC-AF Investigators","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2026.500956_bib0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation. OCEANIC-AF Steering Committee and Investigators","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"LIBREXIA AF trial Investigators and Committees. Milvexian vs. apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.arteri.2026.500956_bib0225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10557-025-07741-x","article-title":"Factor XIa inhibitors versus direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Shahid","year":"2026","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.arteri.2026.500956_bib0230","doi-asserted-by":"crossref","first-page":"102739","DOI":"10.1016\/j.hrtlng.2026.102739","article-title":"Factor XI inhibitors versus direct oral anticoagulants for the prevention of thromboembolic events and safety in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"De Alc\u00e2ntara","year":"2026","journal-title":"Heart Lung"},{"key":"10.1016\/j.arteri.2026.500956_bib0235","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischeic attack: A guideline from American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2026.500956_bib0240","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): An international, randomised, double-blind, placebo-controlled, phase 2b trial. PACIFIC-Stroke Investigators","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2026.500956_bib0245","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficcy of factor XIa inhibition with milvexian for secondary prevention (AXIOMATIC-SSP): a pase 2, international, randomised, double-blind, placebo-controlled, doce-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arteri.2026.500956_bib0250","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"OCEANIC-STROKE Investigators. Asundexian for Secondary Stroke Prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"ATLAS ACS 2\u2013TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500956_bib0260","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A Multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xia inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction; PACIFIC AMI Investigators","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916826000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916826000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:18:58Z","timestamp":1783369138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916826000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S0214916826000653"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500956","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Papel de los inhibidores del factor xi como nueva estrategia anticoagulante en la prevenci\u00f3n y tratamiento de la trombosis arterial","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}],"article-number":"500956"}}